Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
38.81
-0.95 (-2.39%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Edgewise Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Edgewise Therapeutics stock has a consensus rating of "Buy" and an average price target of $49.92. The average 1-year stock price forecast is 28.63% higher than the current stock price, while the lowest is $30 (-22.70%) and the highest is $66 (+70.06%).
Price Target: $49.92 (+28.63%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Edgewise Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 8 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $51 | Buy | Initiates | $51 | +31.41% | Jul 9, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $41 → $51 | Buy | Maintains | $41 → $51 | +31.41% | Jul 6, 2026 |
| Wedbush | Wedbush | Buy Maintains $52 | Buy | Maintains | $52 | +33.99% | Jun 17, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 17, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $48 → $59 | Buy | Reiterates | $48 → $59 | +52.02% | Jun 17, 2026 |
Financial Forecast
Revenue This Year
209.38M
Revenue Next Year
46.67M
from 209.38M
Decreased by -77.71%
EPS This Year
-0.23
from -1.63
EPS Next Year
-1.52
from -0.23
EPS and Forward PE are based on non-GAAP adjusted numbers.